Strand Life Sciences, a Reliance subsidiary, Launches Pioneering Blood-based Test for Early Detection of Multiple Cancers

Bengaluru: Leading genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments.

CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood. CancerSpot’s signatures, derived from Indian cohorts, have been shown to be robust and applicable across global ethnicities. The test provides a simple and convenient option for proactive and routine cancer screening.